Birchview Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Birchview Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-40,000	Closed	-$358K	–	72
2025 Q2	$358K	Hold	40,000	–	–	0.36%	48
2025 Q1	$300K	Hold	40,000	–	–	0.26%	45
2024 Q4	$301K	Hold	40,000	–	–	0.24%	47
2024 Q3	$304K	Hold	40,000	–	–	0.26%	46
2024 Q2	$247K	Buy	40,000 +20,000	+100%	+$110K	0.23%	47
2024 Q1	$102K	Hold	20,000	–	–	0.08%	56
2023 Q4	$120K	Hold	20,000	–	–	0.09%	54
2023 Q3	$142K	Hold	20,000	–	–	0.12%	49
2023 Q2	$141K	Hold	20,000	–	–	0.11%	50
2023 Q1	$167K	Hold	20,000	–	–	0.13%	47
2022 Q4	$230K	Hold	20,000	–	–	0.16%	47
2022 Q3	$252K	Hold	20,000	–	–	0.18%	50
2022 Q2	$212K	Hold	20,000	–	–	0.15%	50
2022 Q1	$325K	Hold	20,000	–	–	0.23%	49
2021 Q4	$277K	Hold	20,000	–	–	0.18%	56
2021 Q3	$287K	Hold	20,000	–	–	0.2%	54
2021 Q2	$316K	Hold	20,000	–	–	0.19%	54
2021 Q1	$203K	Hold	20,000	–	–	0.12%	52
2020 Q4	$149K	Hold	20,000	–	–	0.09%	47
2020 Q3	$69K	Hold	20,000	–	–	0.05%	50
2020 Q2	$95K	Hold	20,000	–	–	0.06%	51
2020 Q1	$40K	Hold	20,000	–	–	0.04%	46
2019 Q4	$69K	Hold	20,000	–	–	0.05%	52
2019 Q3	$57K	Hold	20,000	–	–	0.04%	49
2019 Q2	$76K	Buy	+20,000	New	+$120K	0.05%	50

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Birchview Capital's BCRX Position: Q3 2025 in Review

Birchview Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 40,000 shares — an estimated $358K sold.

Birchview Capital first reported a position in BCRX in Q2 2019 and held it in 25 quarters. The position peaked at $358K in Q2 2025. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

Birchview Capital reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Birchview Capital sold 40,000 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $358K.
Birchview Capital first reported a position in BioCryst Pharmaceuticals in Q2 2019 and held it in 25 quarters.
Birchview Capital's BioCryst Pharmaceuticals position peaked at $358K in Q2 2025.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Birchview Capital's 13F filing for Q3 2025, filed 13 Nov 2025.